A Phase 1, First-in-Human, Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Latest Information Update: 16 Jul 2024
At a glance
- Drugs EVT 801 (Primary)
- Indications Colon cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Kazia Therapeutics
- 01 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 01 May 2024 According to a Kazia Therapeutics media release, the company plans to share final results from this trial at an upcoming scientific conference in the second half of 2024.
- 01 May 2024 Results published in the Media Release